Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 63

1.

Test and treat for TB-HIV.

Ridzon R.

Int J Tuberc Lung Dis. 2017 Dec 1;21(12):1208. doi: 10.5588/ijtld.17.0728. No abstract available.

PMID:
29297437
2.

Interventions to Drive Uptake of Voluntary Medical Male Circumcision-A Collection of Impact Evaluation Evidence.

Sgaier SK, Reed JB, Sundaram M, Brown A, Djimeu E, Ridzon R.

J Acquir Immune Defic Syndr. 2016 Oct 1;72 Suppl 4:S257-S261. No abstract available.

3.

Employing Demand-Based Volumetric Forecasting to Identify Potential for and Roles of Devices in Scale-Up of Medical Male Circumcision in Zambia and Zimbabwe.

Fram F, Church F, Sundaram M, Sgaier SK, Ridzon R, Eletskaya M, Nanga A, Gumede-Moyo S, Tambatamba B, Mugurungi O, Ncube G, Xabayu S, Odawo P, Kretschmer S.

J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S83-9. doi: 10.1097/QAI.0000000000000991.

4.

Innovative Methods of Male Circumcision for HIV Prevention-Getting the Right Evidence.

Samuelson J, Hargreave T, Ridzon R, Farley T.

J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S5-S12. doi: 10.1097/QAI.0000000000000738.

5.

VMMC Devices-Introducing a New Innovation to a Public Health Intervention.

Ridzon R, Reed JB, Sgaier SK, Hankins C.

J Acquir Immune Defic Syndr. 2016 Jun 1;72 Suppl 1:S1-4. doi: 10.1097/QAI.0000000000000967. No abstract available.

6.

Notes from the Field: Tetanus Cases After Voluntary Medical Male Circumcision for HIV Prevention--Eastern and Southern Africa, 2012-2015.

Grund JM, Toledo C, Davis SM, Ridzon R, Moturi E, Scobie H, Naouri B, Reed JB, Njeuhmeli E, Thomas AG, Benson FN, Sirengo MW, Muyenzi LN, Lija GJ, Rogers JH, Mwanasalli S, Odoyo-June E, Wamai N, Kabuye G, Zulu JE, Aceng JR, Bock N.

MMWR Morb Mortal Wkly Rep. 2016 Jan 22;65(2):36-7. doi: 10.15585/mmwr.mm6502a5.

7.

The Vancouver Consensus: antiretroviral medicines, medical evidence, and political will.

Beyrer C, Birx DL, Bekker LG, Barré-Sinoussi F, Cahn P, Dybul MR, Eholié SP, Kavanagh MM, Katabira ET, Lundgren JD, Mworeko L, Pala M, Puttanakit T, Ryan O, Sidibé M, Montaner JS; Vancouver Consensus Signatories.

Lancet. 2015 Aug 8;386(9993):505-7. doi: 10.1016/S0140-6736(15)61458-1. No abstract available.

PMID:
26293427
8.

Voluntary medical male circumcision: an HIV prevention priority for PEPFAR.

Reed JB, Njeuhmeli E, Thomas AG, Bacon MC, Bailey R, Cherutich P, Curran K, Dickson K, Farley T, Hankins C, Hatzold K, Justman J, Mwandi Z, Nkinsi L, Ridzon R, Ryan C, Bock N.

J Acquir Immune Defic Syndr. 2012 Aug 15;60 Suppl 3:S88-95. doi: 10.1097/QAI.0b013e31825cac4e. Review.

9.

Epidemic Intelligence Service investigations of respiratory illness, 1946-2005.

Hadler SC, Castro KG, Dowdle W, Hicks L, Noble G, Ridzon R.

Am J Epidemiol. 2011 Dec 1;174(11 Suppl):S36-46. doi: 10.1093/aje/kwr309.

PMID:
22135392
10.

Antiretroviral therapy in prevention of HIV and TB: update on current research efforts.

Granich R, Gupta S, Suthar AB, Smyth C, Hoos D, Vitoria M, Simao M, Hankins C, Schwartlander B, Ridzon R, Bazin B, Williams B, Lo YR, McClure C, Montaner J, Hirnschall G; ART in Prevention of HIV and TB Research Writing Group.

Curr HIV Res. 2011 Sep;9(6):446-69. Review.

11.

Protease inhibitor-containing antiretroviral treatment and tuberculosis: can rifabutin fill the breach?

Loeliger A, Suthar AB, Ripin D, Glaziou P, O'Brien M, Renaud-Thery F, Crowley S, Williams B, Ridzon R, Granich R, Gilks C.

Int J Tuberc Lung Dis. 2012 Jan;16(1):6-15. doi: 10.5588/ijtld.10.0626. Epub 2011 Aug 3. Review.

PMID:
21819645
12.

More and better information to tackle HIV epidemics: towards improved HIV incidence assays.

Incidence Assay Critical Path Working Group.

PLoS Med. 2011 Jun;8(6):e1001045. doi: 10.1371/journal.pmed.1001045. Epub 2011 Jun 14. No abstract available. Erratum in: PLoS Med. 2011 Jul;8(7). doi:10.1371/annotation/0931760c-95fa-441c-a797-7b410a4c9326. Mastro, Timothy [added].

13.

The challenge of defining standards of prevention in HIV prevention trials.

Philpott S, Heise L, McGrory E, Paxton L, Hankins C; participants in the 2009 GCM/CDC/UNAIDS Consultation on Standards of Prevention in HIV Prevention Trials.

J Med Ethics. 2011 Apr;37(4):244-8. doi: 10.1136/jme.2010.037176. Epub 2010 Dec 24.

PMID:
21186207
14.

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.

Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea P, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SP, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez AI, Burns DN, Glidden DV; iPrEx Study Team.

N Engl J Med. 2010 Dec 30;363(27):2587-99. doi: 10.1056/NEJMoa1011205. Epub 2010 Nov 23.

15.

Implications of HIV PrEP trials results.

Veronese F, Anton P, Fletcher CV, DeGruttola V, McGowan I, Becker S, Zwerski S, Burns D; Workshop Organizing Committee.

AIDS Res Hum Retroviruses. 2011 Jan;27(1):81-90. doi: 10.1089/AID.2010.0226. Epub 2010 Dec 12.

16.

Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial.

Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C; Partners in Prevention HSV/HIV Transmission Study Team.

Lancet. 2010 Mar 6;375(9717):824-33. doi: 10.1016/S0140-6736(09)62038-9. Epub 2010 Feb 12.

17.

Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.

Celum C, Wald A, Lingappa JR, Magaret AS, Wang RS, Mugo N, Mujugira A, Baeten JM, Mullins JI, Hughes JP, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Stevens W, Campbell MS, Thomas KK, Coombs RW, Morrow R, Whittington WL, McElrath MJ, Barnes L, Ridzon R, Corey L; Partners in Prevention HSV/HIV Transmission Study Team.

N Engl J Med. 2010 Feb 4;362(5):427-39. doi: 10.1056/NEJMoa0904849. Epub 2010 Jan 20.

18.

Accuracy of serological assays for detection of recent infection with HIV and estimation of population incidence: a systematic review.

Guy R, Gold J, Calleja JM, Kim AA, Parekh B, Busch M, Rehle T, Hargrove J, Remis RS, Kaldor JM; WHO Working Group on HIV Incidence Assays.

Lancet Infect Dis. 2009 Dec;9(12):747-59. doi: 10.1016/S1473-3099(09)70300-7. Review. Erratum in: Lancet Infect Dis. 2010 Feb;10(2):82.

PMID:
19926035
19.

Circumcision in HIV-infected men and its effect on HIV transmission to female partners in Rakai, Uganda: a randomised controlled trial.

Wawer MJ, Makumbi F, Kigozi G, Serwadda D, Watya S, Nalugoda F, Buwembo D, Ssempijja V, Kiwanuka N, Moulton LH, Sewankambo NK, Reynolds SJ, Quinn TC, Opendi P, Iga B, Ridzon R, Laeyendecker O, Gray RH.

Lancet. 2009 Jul 18;374(9685):229-37. doi: 10.1016/S0140-6736(09)60998-3.

20.

Male circumcision for the prevention of HSV-2 and HPV infections.

Ridzon R, Singh K.

N Engl J Med. 2009 Jul 16;361(3):307; author reply 307-8. No abstract available.

PMID:
19610160

Supplemental Content

Loading ...
Support Center